Wednesday, July 2, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > News > Felicitex Therapeutics Proposes IPO

Felicitex Therapeutics Proposes IPO

in News
Felicitex Therapeutics Proposes IPO
Share on LinkedinShare on WhatsApp

Felicitex Therapeutics said in a filing that it is considering offering 2.5M units priced at $6.25 per unit. That price could change. The Natick, Massachusetts-based company hopes to list its shares on Nasdaq under the symbol FLCT.

This oncology drug development company specializes in, therapies that target dormant cancer cells. When cancer cells are dormant, they can become therapy-resistant, metastasize, and recur. Felixitex is developing treatments that target both dormant and proliferating cancers for the deadliest and most therapy-resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.

Each IPO unit would consist of one share plus two warrants to buy one share apiece at the IPO price. The warrant exercise price would be reset after 90 days of issuance to a price that is at least 50% of the IPO unit price. Underwriters would receive a 45-day option to buy up to 372K additional shares and/or up to 744K warrants to cover any over-allotments. IPO proceeds will help fund research & development subsidize general corporate purposes and provide working capital. Aegis Capital Corp. is the sole underwriter on the deal. 

Tags: CancerFelicitex TherapeuticsIPOPharmacuetical

Related Posts

Hyundai and Kia to adopt Tesla EV chargers
News

Tesla stock rises as company reports steep sales decline

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured
News

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured

Del Monte Foods files for bankruptsy
News

Del Monte Foods files for bankruptsy

US job availability drops to new two-year low
News

Jobs report shows unexpected increase

“Big Beautiful Bill” all-nighter divides Senate
News

“Big Beautiful Bill” all-nighter divides Senate

Musk-Trump tensions escalate
News

Musk-Trump tensions escalate

Hyatt sells Playa portfolio for $2 billion
News

Hyatt sells Playa portfolio for $2 billion

TikTok’s day in court arrives
News

Trump awaits China’s approval for TikTok buyer group

Buffett: AI scams are the next big ‘growth industry’
News

Philanthropist Warren Buffett donates $6 billion in shares

Senior U.S. officials visit China for high-level economic talks
News

US, China formalize trade deal

No Result
View All Result

Recent Posts

  • Nasdaq’s New Survey Reveals: Next-Gen Investors Embrace Advanced Technology ETFs
  • Blackstone’s Jon Gray on Strategic Discipline, AI, and Entrepreneurial Leadership
  • Tesla stock rises as company reports steep sales decline
  • ‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured
  • Del Monte Foods files for bankruptsy

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.